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A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) to
develop evidence-based and consensus-based recommendations for the long-term pharmacologic treat-
ment of restless legs syndrome/Willis–Ekbom disease (RLS/WED). The Task Force reviewed the results of
all studies of RLS/WED treatments with durations of 6 months or longer presented at meetings over the
past 2 years, posted on Web sites of pharmaceutical companies, or published in peer-reviewed journals,
asking the questions, ‘‘What is the efﬁcacy of this treatment in patients with RLS/WED?’’ and ‘‘What is the
safety of this treatment in patients with RLS/WED?’’
The Task Force developed guidelines based on their review of 61 papers meeting inclusion criteria, and
using a modiﬁed evidence-grading scheme. Pregabalin has been established as effective for up to 1 year
in treating RLS/WED (Level A evidence). Pramipexole, ropinirole, and rotigotine have been established as
effective for up to 6 months in treating RLS/WED (Level A). The following drugs have been established as
probably effective (Level B) in treating RLS/WED for durations ranging from 1 to 5 years: gabapentin
enacarbil, pramipexole, and ropinirole (1 year); levodopa (2 years); and rotigotine (5 years). Because of
associated safety concerns, pergolide and cabergoline should not be used in the treatment of RLS/WED
unless the beneﬁts clearly outweigh the risks. Other pharmacologic therapies have insufﬁcient evidence
to support their long-term use in treating RLS/WED.
The IRLSSG Task Force also developed consensus-based strategies for the prevention and treatment of
complications (such as augmentation, loss of efﬁcacy, excessive daytime sleepiness, and impulse control
disorders) that may develop with the long-term pharmacologic treatment of RLS/WED. The use of either a
dopamine-receptor agonist or a2d calcium-channel ligand is recommended as the ﬁrst-line treatment of
RLS/WED for most patients, with the choice of agent dependent on the patient’s severity of RLS/WED
symptoms, cognitive status, history, and comorbid conditions.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.
676 D. Garcia-Borreguero et al. / Sleep Medicine 14 (2013) 675–6841. Introduction 3.2. Outcome measuresRestless legs syndrome (RLS), also known as Willis–Ekbom dis-
ease (WED), is a commonly occurring neurologic disorder charac-
terized by an irresistible urge to move the legs, usually
accompanied by dysesthesias that are relieved by movement, exac-
erbated by rest, and worse in the evening and night [1]. Sleep and
quality of life can be severely affected [2–5].
RLS/WED was largely unrecognized until the 1990s when stud-
ies documenting its clinical relevance were conducted and signiﬁ-
cant epidemiologic studies revealed RLS/WED to be a notable
public health concern [6]. To date, evidence-based treatment
guidelines [7–13] have been primarily based on studies lasting
no longer than 12 weeks, whereas RLS/WED quite often is a lifelong
disease [14]. Long-term clinical experience with the treatment of
patients with RLS/WED has revealed both the signiﬁcance of prob-
lems that arise during the short term (e.g., weight gain, impulse
control disorders [ICDs], mood disturbances) and the emergence
of new problems during long-term treatment (e.g., augmentation,
loss of efﬁcacy). Thus the current evidenced-based guidelines do
not sufﬁce for providing clinical guidance for the long-term treat-
ment of RLS/WED.2. Process and objectives
2.1. Task Force
The Executive Committee of the International RLS Study Group
(IRLSSG) established an international Task Force to develop recom-
mendations for the long-term treatment of RLS/WED. The mem-
bers of the Task Force completed the IRLSSG conﬂict of interest
statement (Appendix–Conﬂict of interest disclosures). Financial
support for this endeavor was requested from all pharmaceutical
companies involved in the treatment of RLS/WED; funding was
ultimately provided by unrestricted education grants from Xeno-
port and UCB Pharma. Funders did not participate in the develop-
ment of these guidelines and recommendations, and they were not
privy to this document before publication.2.2. Objectives
The objectives of the Task Force were (1) to develop evidence-
based guidelines for the efﬁcacy and safety of pharmacologic
agents for the long-term treatment of RLS/WED and (2) given the
limitations of current data, to complement these with consensus-
based recommendations of experts regarding the long-term
treatment of RLS/WED and management of common complications
that may arise.3. Methods
3.1. Literature search and strategy
Databases that were searched included MedLINE, CINAHL, clin-
icaltrials.gov, abstracts from key 2010 and 2011 meetings, and
drug company Web sites using the freeform search term of restless
legs syndrome in combination with each of the following terms:
treatment, therapy, and drugs and the MeSH term restless legs syn-
drome, therapeutics. Inclusion criteria were any pharmacologic
treatment of adults with RLS/WED, with the results published in
any language over any timeframe and with a study duration of a
minimum of 6 months. A review of the literature search strategy
is detailed in the Appendix (Detailed literature search and data
extraction).An overview of the primary tools used in RLS/WED trials to
measure the efﬁcacy of long-term pharmacologic treatments is
provided in Table 1.
3.3. Data extraction and evaluation of the evidence
Evidence was graded based on Agency for Healthcare Research
and Quality [15] and European Federation of Neurological Societies
[16] systems, which were then adapted to support the evaluation
of long-term treatment studies. Developing long-term treatment
guidelines is complicated both by the limited number of studies
of sufﬁcient duration (i.e.,P6 months) and also by the need to ad-
just evidence criteria, taking into account the types of studies
appropriate to convincingly document evidence of long-term treat-
ments. In particular, obtaining data on efﬁcacy for treatments of
1–10 years or longer generally would require retrospective or
planned prospective case series. When these studies were per-
formed well and met the criteria for Class III evidence except that
they were prospective open-label studies or case series and not
controlled trials, it was felt that they provided useful information
for making a recommendation. Therefore, two subcategories were
added to Class III (Tables 2 and 3) for prospective open-label stud-
ies and for prospective and retrospective case series without con-
trol groups (henceforth, the original Class III is denoted as Class
IIIaIRLSSG; the prospective open-label studies as Class IIIbIRLSSG;
and the prospective and retrospective case series without control
groups as Class IIIcIRLSSG). We felt that this was in line with the
intention of the original Class III when applied to long-term stud-
ies. Data extraction is described in the online Appendix (Detailed
literature search and data extraction).
3.4. Consensus-based clinical recommendations
Consensus was deﬁned by at least 80% of the members of the
Task Force agreeing on a clinical recommendation.
3.5. Approval of treatment recommendations
Summaries of both the evidenced-based and the consensus-
based treatment recommendations were prepared and presented
at the annual meeting of the IRLSSG on June 9, 2012, in Boston,
Massachusetts. In addition, an e-mail was sent to all IRLSSG mem-
bers with a link to an online copy of the recommendations. Mem-
bers were given an opportunity to comment on the
recommendations from June 9 to June 24, 2012. The Executive
Committee of the IRLSSG approved the ﬁnal recommendations on
July 17, 2012.
4. Evidence-based guidelines for the long-term pharmacologic
treatment of RLS/WED
Sixteen pharmacologic agents have been studied for the treat-
ment of RLS/WED for at least 6 months. The following sections re-
view the evidence and provide evidenced-based recommendations
for each drug. The evidence discussed below is presented by study
in the online Appendix (Table A1); a summary of the ﬁnal evi-
denced-based recommendations is provided in Table 4.
4.1. Dopaminergic agents
4.1.1. Non-ergot-derived dopamine-receptor agonists
4.1.1.1. Pramipexole. double-blind 26-week study [17] (Class I)
randomly assigned 331 patients with idiopathic RLS/WED to
Table 1
Overview of tools frequently used for the investigation of RLS/WED in clinical trials.
Objective Method Description
Severity of
RLS/WED
IRLSSG severity rating
scale
P/I: 10 items covering the severity and frequency of RLS/WED symptoms, sleep disturbance, daytime tiredness, impact of
symptoms on daily activities, and mood; total score (maximum 40) and two subscales: symptom severity and symptom
impact
RLS-6 scales P: six global scales on the severity of RLS/WED symptoms at bedtime, during the night, during the day when at rest or
when involved in activities, on satisfaction with sleep, and on tiredness or sleepiness during the day. No total score is
calculated, but items are individually evaluated to proﬁle changes in symptoms over time
Clinical global
impressions
I: four scales are used to capture global impressions of investigators on severity and changes during treatment: severity of
disease, general change from baseline, therapeutic effect, and impact of side effects
Augmentation Augmentation severity
rating scale
P/I: three items are used to assess the severity of augmentation: earlier onset of symptoms, shorter latency to symptom
occurrence at rest, and spreading to other body parts. Augmentation severity is represented in a total score
Abbreviations: RLS, restless legs syndrome; WED, Willis–Ekbom disease; IRLSSG, International Restless Legs Syndrome Study Group; P, assessed by the patient; I, assessed by
the investigator; P/I, assessed by both patient and investigator.
Table 2
Evidence classiﬁcation scheme developed by the International Restless Legs Syndrome Study Group for evaluating long-term studies of therapeutic interventions for restless legs
syndrome/Willis–Ekbom disease.
Class Description
I An adequately powered prospective, randomized, controlled, clinical trial with masked outcome assessment in a representative population or an adequately
powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations
The following 5 criteria must be met:
 Randomization is concealed
 Primary outcomes are clearly deﬁned
 Exclusion and inclusion criteria are clearly deﬁned
 Dropouts and crossovers are adequately accounted for, with numbers sufﬁciently low to have minimal potential for bias
 Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for
differences
II Prospective, matched-group, cohort study in a representative population with masked outcome assessment that meets all of the requirements for a Class I study
or a randomized controlled trial in a representative population except that it lacks one of the ﬁve criteria for a Class I study
III Any of the following study designs qualify
aIRLSSG. A controlled trial that includes well-deﬁned natural history control subjects or patients serving as their own controls in a representative population in
which outcome assessment is independent of patient treatment
bIRLSSG. A large prospective case series or prospective open-label clinical trial in a representative population, in which outcome assessment is well-deﬁned and
is independent of patient treatment
cIRLSSG. A large retrospective case series or retrospective evaluation of data from a clinical trial in a representative population, in which outcome assessment is
well-deﬁned and is independent of patient treatment
IV An uncontrolled study, case series, case reports, or expert opinion
Adapted from Agency for Healthcare Research and Quality [15] and European Federation of Neurological Societies [16].
Table 3
Rating of recommendations for therapeutic interventions.
Rating Requires at least Intervention is
A One convincing Class I study or at least two consistent, convincing,
Class II studies
Effective, ineffective, or harmful
B One convincing Class II study or overwhelminga Class IIIIRLSSG evidence Probably effective, probably ineffective, or probably harmful
C Two convincing Class IIIIRLSSG studies. Possibly effective, possibly ineffective, or possibly harmful
Good practice points Consensus of expert opinion
a Overwhelming was interpreted for long-term studies to mean either one large well-deﬁned prospective study of a long duration (3 or more y) with clear outcome results
or several class III studies with almost all having the same result.
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showed superiority of pramipexole. A double-blind, 52-week,
ﬁxed-dose study [18] (Class I) randomly assigned 719 patients to
1 of 2 pramipexole doses (0.25 or 0.5 mg daily) or pregabalin
(300-mg daily). After 1 year, pregabalin showed superior efﬁcacy
to both the 0.25-mg and 0.5-mg doses of pramipexole. Patients im-
proved markedly under pramipexole; however, the study did not
include a placebo in the long-term treatment period, the study
was considered to provide Class II evidence. One Class IIIaIRLSSG
9-month study of 150 patients who had responded to pramipexole
during a 6-month run-in period showed improvement in symp-
toms, sleep, and quality of life and no decline in the beneﬁt and tol-
erability of pramipexole [19].
The long-term efﬁcacy of pramipexole in ﬂexible doses be-
tween 0.125- and 0.75-mg daily for 6 months or up to 1 year alsowas supported by two Class IIIbIRLSSG studies [20,21]. In these
studies, patients’ symptoms improved to an average severity level
of mild. Five retrospective, large-scale (50–195 patients) case ser-
ies (Class IIIcIRLSSG) have analyzed the course of pramipexole ther-
apy in routine practice of single centers for treatment periods
between 2 and 10 years [22–26]. The mean dose of pramipexole
was 0.125–0.75-mg daily, but the dose was increased to 2.5-mg
daily [23] or 3.75-mg daily in individual patients [22]. Dose in-
creases occurred in all ﬂexible-dose studies, as indicated by high-
er mean doses of pramipexole at the end of the observation
period compared with the time when treatment started. In addi-
tion, the results of two small Class IV case series with a mean
observation time of 7.8 [27] and 39.2 [28] months support the
ﬁndings of the efﬁcacy of pramipexole under the conditions of
routine practice.
Table 4
Evidence from clinical trials has shown the following commonly used drugs to be
effective or probably effective for at least these durations.
Drug Effective Probably effective
Pramipexole 6 mo 1 y
Ropinirole 6 mo 1 y
Rotigotine 6 mo 5 y
Levodopa –a 2 y
Gabapentin enacarbil – 1 y
Pregabalin 1 y –
Gabapentin – –
Abbreviations: mo, months; y, years.
a Indicates insufﬁcient evidence to make a recommendation.
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document the retention rate under therapy, often evaluated with
its reverse measure, the rate of dropouts. Whether due to augmen-
tation, adverse events (AEs), loss of efﬁcacy, or loss to follow-up,
dropout rates varied between 10% [22] and 22% [23] for a treat-
ment period of 2–3 years. Silver et al [25] reported discontinuation
rates of 17% during the ﬁrst year; from years 2 to 10, this rate was
fairly constant at 9% per year.
The most frequent AEs associated with the use of pramipexole
in all of these studies are those well-known to be associated with
the use of dopamine-receptor agonists: sleepiness (5–56%), nausea
(12–25%), and insomnia (7–16%). These AEs occurred more com-
monly in the ﬁrst months after the initiation of treatment than
during the long-term therapy.
Recommendation: Pramipexole is effective for the treatment
of RLS/WED for up to 6 months (Level A) and probably effective
for 1 year (Level B). Pramipexole is also possibly effective for up
to 10 years in the 10–40% of patients who tolerate therapy and
do not experience augmentation or loss of efﬁcacy.
4.1.1.2. Ropinirole. One Class I study [29] investigated the efﬁcacy
of ropinirole for a period of 6 months. This randomized, double-
blind, placebo-controlled study of 404 patients with severe idio-
pathic RLS/WED (IRLSSG Rating Scale [IRLS] baseline score: 27.6
units) showed a small (by 2.5 IRLS units) but statistically signiﬁ-
cant superiority of ropinirole (median dose: 1.8 mg/d, range: 0.4–
3.6-mg, ﬂexible-dose design) over placebo.
One Class IIIaIRLSSG study [30] used a randomized withdrawal
design: 206 patients were treated for 24 weeks in an open-label
portion of the study with a median dose of ropinirole of 2.0-mg
daily (range, 0.25–4.0 mg); 47.5% of patients dropped out of the
study, mainly due to AEs (18.3%). In a second (i.e., double-blind)
part of the study, the 92 patients whose symptoms responded to
treatment with ropinirole (45.5% of the original population) were
randomly assigned to continue ropinirole treatment or switch to
placebo for an additional 12 weeks. The relapse rate was lower in
those patients who received ropinirole (32.6%), as compared with
those who received placebo (57.8%).
Two Class IIIbIRLSSG, open-label, prospective studies [31,32] with
large sample sizes showed improvement of symptom severity to a
mild level under median ropinirole doses of 1.6- or 2.0-mg daily
(ranges, 0.25–4.0 mg) after 1 year. In addition, two Class IV retro-
spective [28] or mixed retrospective and prospective [33] case ser-
ies were conducted in which small numbers of patients (n = 8–36)
received ropinirole for a mean duration of between 10 and
39 months.
AEs in studies of ropinirole were those known to occur with the
use of dopamine-receptor agonists: nausea (25–50%), headache(7–22%), fatigue (1–19%), dizziness (6–18%), and vomiting (5–
11%). These AEs occurred more commonly in the ﬁrst months after
the initiation of treatment than during the long-term therapy.
Recommendation: Ropinirole is effective for the treatment of
RLS/WED for 6 months (Level A) and is probably effective for 1 year
(Level B). There is insufﬁcient evidence documenting the effective-
ness of ropinirole to make a recommendation beyond 1 year of
treatment.
4.1.1.3. Rotigotine. Two double-blind, randomized, ﬁxed-dose stud-
ies (Class I) evaluated the rotigotine transdermal delivery system
(patch application once daily for 24 h) for patients with moderate
to severe idiopathic RLS/WED for 6 months [34,35]. In addition, 2
prospective, open-label, 1-year, extension studies [36,37] of the 2
double-blind studies and a prospective, open-label, 5-year, long-
term study [38] were conducted (Class IIIbIRLSSG).
The ﬁrst study was from a European sample of 458 patients
with ﬁxed rotigotine doses of 1, 2, or 3 mg per 24 hours [35]. Sev-
enty percent of patients completed the study. All doses were signif-
icantly efﬁcacious compared with placebo based on the primary
end points of the IRLS and Clinical Global Impression Severity
Scale.
The second randomized, double-blind, 6-month study included
505 patients in the United States who used ﬁxed doses of 0.5, 1, 2,
or 3 mg per 24 hours compared with placebo [34]. Sixty-three per-
cent of patients completed the study. Only the 2- and 3-mg doses
were superior to placebo, based on the coprimary end points of
IRLS and Clinical Global Impression Severity Scale.
Two prospective, open-label, ﬂexible-dose studies (Class
IIIbIRLSSG) evaluated rotigotine treatment for moderate to severe
RLS for 1 year [36,37]. The mean rotigotine doses (ﬂexible dosing)
were 1.89 [36] and 2.08 [37] mg per 24 hours (range, 0.5–3 mg/
24 h). Both studies showed symptom reduction to an average level
of mild symptoms beginning within 1 week and continuing for
1 year for most patients.
Long-term maintenance of efﬁcacy also was demonstrated in
the longest prospective clinical trial in RLS research (Class
IIIbIRLSSG) [38]. The mean rotigotine dose after initial titration was
2.4 mg per 24 hours and increased, on average, to 3.1 mg per
24 hours at the end of the 5-year study. Of the 295 patients initially
enrolled in the study, 126 (43%) completed 5 years of therapy,
receiving ﬂexible rotigotine doses between 0.5 and 4 mg per
24 hours. Thirty-nine percent of the patients who completed the
study were considered to be free of all RLS symptoms, providing
overwhelming evidence of the efﬁcacy.
AEs were mostly application-site reactions to the patch (22–
58%). Other systemic AEs, such as nausea (7–19%), headache
(4.1–10.8%), and fatigue (0.5–11%), occurred more frequently in pa-
tients receiving higher rotigotine doses. AEs occurred with
decreasing frequency over time, as in other studies with dopami-
nergic medications, with the highest incidence occurring in the
ﬁrst few months after start of therapy.
Recommendations: Rotigotine is effective in the treatment of
RLS/WED for 6 months (Level A). Rotigotine also is probably effec-
tive for up to 5 years in the approximately 43% of patients who tol-
erate the therapy and who do not experience augmentation and
loss of efﬁcacy (Level B).
4.1.1.4. Piribedil. Eleven of 13 patients in a prospective case series
(Class IV) [39] who received open-label piribedil at a median dose
of 50-mg daily (range, 25–350 mg) for up to 15 months reported
subjective beneﬁts, and eight patients had an RLS score of 0 after
treatment.
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of piribedil in the long-term treatment of
RLS/WED.
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4.1.2.1. Levodopa–carbidopa or levodopa–benserazide. Six studies
evaluated the safety and efﬁcacy of levodopa–carbidopa or levo-
dopa–benserazide. A randomized, double-blind, multicenter study
conducted in Europe compared levodopa–benserazide and cabergo-
line in a 30-week evaluation (core study) [40] and a double-blind
extension for up to 2 years [41]. Cabergoline (dose level, 2 or 3 mg/
d)was superior to levodopa (dose level, 200 or 300 mg/d) in improv-
ing RLS/WED symptom severity on the IRLS in both the core and
long-term study. Although the authors commented that levodopa
provided signiﬁcant symptom relief, these studies provided only
Class II evidence for levodopa because they lacked a placebo arm.
Two prospective Class IIIbIRLSSG studies [42,43], one Class
IIIcIRLSSG study [44], and a small case series (Class IV) [45] provided
further evidence for the efﬁcacy of levodopa preparations when
used in doses between 200- and 700-mg daily for a duration of be-
tween 6 and 31 months.
Considering the concatenated core and extension study [40,41],
24% of patients dropped out during the ﬁrst 30 weeks and an addi-
tional 15.6% dropped out in the next 74 weeks; the most common
cause of patient dropout was augmentation. A similar 40% dropout
rate was reported in the 6-month, open-label, Class IIIbIRLSSG study
[42], with 11.7% due to augmentation, 11.7% due to loss of efﬁcacy,
and 5.0% due to AEs. The most frequent reasons for premature dis-
continuation in all the prospective studies were loss of efﬁcacy,
AEs, and augmentation. Across all studies, the most frequent AE
was nausea, which was more frequently observed in the ﬁrst
months after start of therapy than under long-term treatment
(9.3% vs 1.3% in the core and extension comparative studies of
levodopa vs cabergoline).
Recommendation: Levodopa is probably effective for up to
2 years for the treatment of RLS/WED in the 24–40% of patients
who tolerate therapy and who do not develop augmentation or loss
of efﬁcacy (Level B).
4.1.3. Ergot-derived dopamine-receptor agonists
4.1.3.1. Pergolide and cabergoline. Effectiveness in the long-term
treatment of RLS/WED has been documented for both pergolide
and cabergoline (see Appendix: Evaluating the efﬁcacy of ergot-de-
rived dopamine-receptor agonists). Reports to the US Food and
Drug Administration have shown an association between the use
of these drugs and ﬁbrosis and valvulopathy [46–49]. Pergolide
was voluntarily withdrawn by the manufacturers from the market
in the United States in 2007.
Recommendation: Pergolide and cabergoline should no longer
be used in the treatment of RLS/WED, except for those patients
whose symptoms are refractory to all other treatments and in
whom the beneﬁts outweigh the risks. Patients who receive pergo-
lide or cabergoline should undergo annual cardiac ultrasound
assessments.
4.2. a2d Calcium-channel ligands
4.2.1. Gabapentin enacarbil
One study using a randomized withdrawal design for a period of
36 weeks [50] (Class IIIaIRLSSG) and two open-label extensions of
double-blind controlled trials providing active treatment for 1 year
(Class IIIbIRLSSG) [51,52] provide evidence for the efﬁcacy of gaba-
pentin enacarbil in the long-term treatment of RLS/WED. The dose
range in these studies was between 600 and 1800 mg daily. All
studies showed an average improvement of symptom severity to
a mild level.
AEs primarily occurred in the ﬁrst weeks after commencing the
treatment with gabapentin enacarbil. The most common AEs weresomnolence (19.7–41%), dizziness (11.5–46%), and headache (7.2–
12.6%).
Recommendations: Gabapentin enacarbil is probably effective
for the treatment of RLS/WED for 1 year (Level B). There is insufﬁ-
cient evidence documenting the effectiveness of gabapentin ena-
carbil to make a recommendation beyond 1 year of treatment.
4.2.2. Pregabalin
A 52-week, randomized, double-blind study [18] (Class I) com-
pared pregabalin with pramipexole in 719 patients. Following a
4-arm initial placebo-controlled phase for 12 weeks, patients on
placebo were randomly assigned to pregabalin (300 mg/d) or 1 of
2 pramipexole groups (0.25 or 0.5 mg/d). At the 52-week evalua-
tion, the pregabalin group had a statistically signiﬁcant larger
mean decrease in IRLS score from baseline than pramipexole; the
decrease was 3.8 points greater than the decrease in the IRLS score
of the 0.25-mg pramipexole group and 3.1 points greater than that
of the 0.5-mg pramipexole group. However, over 1 year of treat-
ment, more patients taking pregabalin (27.5%) than taking pramip-
exole (0.25 mg, 18.5%; 0.5 mg, 23.9%) discontinued the study due
to AEs. The most frequent AEs in subjects taking 300-mg daily of
pregabalin were dizziness (21%), somnolence (18%), fatigue (11%),
and nausea (10%).
The ﬁndings of one Class IV study [53] that investigated pregab-
alin in 19 patients with secondary RLS/WED due to neuropathy
showed favorable efﬁcacy of pregabalin over a mean of 31 (±17)
weeks with a mean dose of 305 mg daily.
Recommendations: Pregabalin is effective for the treatment of
RLS/WED for 1 year (Level A). There is insufﬁcient evidence docu-
menting the effectiveness of pregabalin to make a recommenda-
tion beyond 1 year of treatment.
4.2.3. Gabapentin
Two Class IV studies [54,55] evaluated ﬂexible doses of gaba-
pentin for the treatment of RLS/WED (300–2400 mg/d) in 16
patients for 6–18 months (median, 8 months) and 8 patients (four
of whommaintained treatment for at least 6 months), respectively.
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of gabapentin in the long-term treatment
of RLS/WED.
4.3. Opioids and opioid-receptor agonists
4.3.1. Tramadol
One Class IV study examined the effects of tramadol at a
mean dose of 100 mg over a mean of 22.8 months in the treatment
of primary RLS/WED [56]. Most patients reported subjective
beneﬁts.
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of tramadol in the long-term treatment of
RLS/WED.
4.3.2. Methadone
One Class IIIcIRLSSG study [25] and one Class IV [57] study
evaluated the use of methadone in the treatment of idiopathic
and secondary RLS/WED. Both studies showed sustained therapeu-
tic beneﬁt over 2–10 years in patients who had failed treatment
with other agents, largely due to augmentation; methadone doses
ranged from 5- to 40-mg daily. Approximately one third of the
patients in these two studies were on concomitant therapy.
Dropout rates ranged from 13% to 30% and were due to lack of
efﬁcacy and AEs (sedation, depression or anxiety, altered
consciousness).
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of methadone in the long-term treatment
of RLS/WED.
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Three case series [58–60] (Class IV) reported on the successful
use of morphine, administered intrathecally via implantable pump
for the treatment of refractory RLS/WED in a total of 13 patients for
a period between 7 months and 3.5 years.
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of intrathecal morphine in the long-term
treatment of RLS/WED.
4.3.4. Multiple opioids
In a retrospective, multicenter, Class IV study conducted in the
United States and Europe (3 sites) [61], 32% of 113 patients were
treated with an opioid monotherapy and 68% received opioids in
combination with other RLS/WED treatments. A broad range of
opioids were administered, with tilidine (25 mg) being the most
commonly prescribed drug in Europe and oxycodone (5 mg) in
the United States. Treatment records covered up to 23 years, with
an average of 3–5 years. Treatment was well-tolerated, but the
authors recommended evaluating patients for sleep apnea.
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of any single opioid in the long-term treat-
ment of RLS/WED.
4.4. Other drugs
4.4.1. Tetrabenazine
One Class IV study showed mild if any beneﬁt in the use of tet-
rabenazine in the treatment of RLS/WED in patients with comorbid
hyperkinetic movement disorders [62].
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of tetrabenazine in the long-term treatment
of RLS/WED.
4.4.2. Iron
Intravenously administered iron sucrose was not found to be
efﬁcacious in two short-term trials [63,64]. One of these trials
[64], which reported dropout rates at 1 year after treatment that
were signiﬁcantly less for iron than placebo, did not, however,
meet its primary end point showing treatment beneﬁt for iron.
One randomized double-blind study (Class I) with ferric carb-
oxymaltose given in two 500-mg doses 5 days apart showed signif-
icant improvement compared with placebo at 4 weeks after
treatment [65]. Patients responding to initial treatment were fol-
lowed up with knowledge of their prior treatment for up to
24 weeks after initial treatment, and 25% of subjects were found
to be free of any signiﬁcant RLS/WED symptoms [65].
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the intravenous use of ferric carboxymaltose or iron
sucrose in the long-term treatment of RLS/WED.
4.4.3. Sedative hypnotics
4.4.3.1. Clonazepam. One Class IV study included 34 patients with
RLS/WED or periodic limb movement disorder treated with clona-
zepam for at least 6 months with a mean initial dose of 0.9 mg,
which increased to 1.35 mg [66].
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of sedative hypnotics in the long-term treat-
ment of RLS/WED.
4.4.4. Levetiracetam
One Class IV study included two patients with severe RLS/WED
and periodic limb movements who had a positive response to
1000 mg of levetiracetam for 21 and 26 months [67].
Recommendation: Evidence is insufﬁcient to make a recom-
mendation on the use of levetiracetam in the long-term treatment
of RLS/WED.5. Consensus-based recommendations for the long-term
treatment of RLS/WED
During a meeting on January 20 to January 22, 2012, in Madrid,
Spain, the Task Force established by the IRLSSG discussed the man-
agement of the primary AEs and complications that arise during
the long-term treatment of RLS/WED and, through consensus
developed practical recommendations. Consensus was reached
when more than 80% of the members of the Task Force agreed
on a given measure.
5.1. Recommendation regarding loss of efﬁcacy and augmentation
Loss of efﬁcacy and augmentation are the main causes of treat-
ment failure that emerge later in the course of treatment of RLS/
WED. Supporting information on these recommendations and
additional details on other AEs that arise in the long-term pharma-
cologic treatment of RLS/WED can be found in the online Appendix
(Adverse events related to the long-term treatment of RLS/WED).
5.1.1. For augmentation and loss of efﬁcacy
 The patient’s serum ferritin level should be measured, and, if
the concentration is lower than 75 lg/mL, supplementation
with orally administered iron is recommended unless poorly
tolerated or contraindicated [68,69].
 It is important to ask the patient about any lifestyle changes,
compliance with the current therapy, changes in medical fac-
tors (use of dopamine-receptor antagonists or antidepressants),
or other extrinsic factors (sleep deprivation, blood loss, alcohol
use) that might have contributed to an earlier onset or an
increase in the severity of symptoms. Any extrinsic factors exac-
erbating RLS expression should be adjusted as much as possible
to reduce the need for medication changes [70].
5.1.2. For loss of efﬁcacy
 Loss of efﬁcacy [71] commonly occurs for all drugs in the long-
term treatment of RLS/WED [26]. If loss of efﬁcacy occurs, doses
of the current agent should only be adjusted above the
approved levels with caution and with monitoring for adverse
effects, development of augmentation, or progressive loss of
efﬁcacy. Instead, consideration should be given to adding
another medication or changing medications.
 For patients experiencing loss of efﬁcacy under monotherapy, a
drug of another class (either dopamine-receptor agonists or a2d
ligands) could either be added without increasing the dose of
the current drug or, alternatively, substituted for the current
drug.
5.1.3. For augmentation
 Augmentation is a major clinical problem that emerges with the
long-term treatment of RLS/WED. It can produce a severe exac-
erbation of RLS/WED symptoms, and is thus something to be
carefully assessed and managed.
 Some degree of augmentation has been reported with the use of
all investigated dopaminergic drugs [25,32,38,40,42] and also
for tramadol [72]. In the virtual absence of direct comparative
studies, the incidence rate seems to be highest during treatment
with levodopa and higher for shorter-acting (pramipexole,
ropinirole) than longer-acting (rotigotine, cabergoline) dopa-
mine-receptor agonists. However, it is unclear whether this
ﬁnding is related to the masking of earlier symptom onset by
the longer-acting dopaminergic agents or if it is truly an aug-
mentation-sparing effect.
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treatment and possibly with higher doses. It is unclear whether
the apparent relationship between dose and augmentation rate
is, in fact, secondary to patient characteristics such as disease
duration or severity. Nevertheless, it is recommended that dose
increases be carefully considered, particularly if they exceed
usually accepted or approved dose levels. They should be lim-
ited to breakthrough of clinically important symptoms that can-
not be managed behaviorally and should be balanced against
the option of adding an alternate type of medication.
 If bothersome earlier onset of symptoms occurs with augmen-
tation when the patient is taking a short-acting dopaminergic
medication, a dose of the current medication can be added ear-
lier, with possible reduction of the later dose, or the medication
can be changed to a single dose of a longer-acting dopaminergic
or other medication. If the total dopaminergic dose is increased,
careful monitoring for progressive augmentation is needed [18].
 For severe or progressive augmentation, the dopamine-receptor
agonist should be discontinued and an a2d ligand, an opioid, or
possibly another (perhaps longer-acting) dopamine-receptor
agonist substituted.5.2. Recommendations for managing other treatment-related
challenges emerging during long-term therapy
5.2.1. For ICDs
 ICDs develop in 6–17% of patients with RLS/WED who take
dopamine-receptor agonists [73]. ICDs may occur more often
with higher doses of drugs and may be more likely to occur in
women.
 Patients should be questioned about ICDs at each visit. If a sig-
niﬁcant ICD is present, the drug should be discontinued or at
least the dose decreased to a level at which the ICDs cease.
Other nondopaminergic drugs should be substituted or added.5.2.2. For comorbid insomnia.
 If problems of insomnia or inadequate sleep develop or persist
on the current medication, then a short-acting GABA active hyp-
notic or an a2d ligand, if not already used, can be added to or
substituted for the current treatment.Table 5
Clinical consensus of the beneﬁts and risks for each pharmacologic treatment of RLS/WED
Levodopa Nonergot DA
Short-acting Long
The potential of the drug to cause the following adverse events
Augmentation +++ ++ +
LoE +++ ++ NK
ICD 0 + 0/+
EDS NK ++ +
Negative mood 0 0 0
Weight gain 0 0 0
General toxicity + + ++
The potential of the drug to have positive effect on these parameters
Subjective nighttime sleep 0 + +
Classic nighttime RLS/WED symptoms + ++ ++
QoL NK ++ ++
Pain reduction + + +
Abbreviations: RLS/WED, restless legs syndrome/Willis–Ekbom disease; DA, dopamine-re
daytime sleepiness; QoL, quality of life; NK, not known.
+++, is very likely to affect this parameter; ++, is somewhat likely to affect this paramet5.3. Recommendations regarding choice of agents
5.3.1. Recommendations for the selection of an agent for initial
treatment of RLS/WED
The IRLSSG Task Force recognizes that choice of agent for the
initial treatment of RLS/WED often affects patients’ ability to toler-
ate the therapy over the long term. Therefore, the Task Force devel-
oped the following recommendations:
 Either dopamine-receptor agonists or the a2d ligands are the
ﬁrst-line treatment for patients with RLS/WED.
 The choice of the initial treatment should be based on the indi-
vidual clinical features of RLS/WED in a given patient (Tables 5
and 6).
 Medication administration should be related to the timing of
the onset of clinically signiﬁcant symptoms that cannot be
effectively managed behaviorally. There is variation in the onset
time of individual medications which needs to be taken into
account.
 Patients with clinically signiﬁcant daytime symptoms should be
treated with a long-acting agent. Multiple daily doses of a short-
acting agent can also be tried. Considerable caution should be
exercised with frequent monitoring for loss of efﬁcacy or the
development or progression of augmentation with all dopami-
nergic agents.
 The use of a2d ligands should be considered for initial treatment
of patients with severe sleep disturbance (disproportionate to
other RLS/WED symptoms), comorbid insomnia or anxiety,
RLS/WED-related or comorbid pain, or a history of an ICD or
anxiety.
 Dopamine-receptor agonists should be considered for initial
treatment of patients with very severe symptoms, excessive
weight, comorbid depression, increased risk of falls, or cognitive
impairment.
 The availability and cost of drugs may need to be considered in
making the choice of the initial treatment.
 Combination treatments of a dopamine-receptor agonist and an
a2d ligand should be considered for patients with symptoms
that cannot be controlled with a low-dose monotherapy of
either treatment class. There is a need for more clinical studies
of combination treatments..
Ergot-based DA a2d Ligand Opioid Clonazepam
-acting
++ 0 NK 0
++ + + NK
NK 0 0 0
++ +++ + ++
0 + + ++
0 ++ 0 0
+++ + ++ +
+ ++ ++ ++
++ ++ ++ 0
++ ++ NK NK
+ ++ +++ 0
ceptor agonist; LoE, loss of efﬁcacy; ICD, impulse control disorders; EDS, excessive
er; +, is slightly likely to affect this parameter; 0, has no effect on this parameter.
Table 6
Clinical recommendations regarding factors that affect the selection of an agent for initial treatment in patients with restless legs syndrome/Willis–
Ekbom disease.
Factor that impacts the choice of agent Treatment choice
Time of day (daytime disturbance)  Preferably a long-acting agent
 Twice a day dosing of a short-acting agent
Sleep disturbance disproportionate to other symptoms of RLS/WED a2d Ligand
Comorbid insomnia a2d Ligand
Pregnancy risk  Avoid both dopaminergic agents and a2d ligands
 Consider the use of iron
Impaired renal function  Select a drug that is not renally excreted
Increased risk for falls Dopamine-receptor agonist
Painful restless legs a2d Ligand
Comorbid pain syndrome a2d Ligand
History of or current ICD a2d Ligand
History of or current alcohol or substance abuse Dopamine-receptor agonist or a2d ligand
Severe symptoms of RLS/WED Dopamine-receptor agonist
Excess weight, metabolic syndrome, or obstructive sleep apnea Dopamine-receptor agonist
Availabilitya Dopamine agonist or a2d ligand
Costb Dopamine agonist or a2d ligand
Comorbid depression Dopamine-receptor agonist
Comorbid generalized anxiety disorder a2d Ligand
Daytime sleepiness  Investigate the cause
Higher potential for drug interactions  Select drug that is not hepatically excreted
Abbreviations: RLS/WED, restless legs syndrome/Willis–Ekbom disease; ICD, impulse control disorder.
a Drugs approved by regulatory agencies as of December 2012 for the treatment of restless legs syndrome/Willis–Ekbom disease (RLS/WED)
include gabapentin enacarbil (United States), levodopa/benserazide (Germany and Switzerland), pramipexole (United States and European
Union), ropinirole (United States and European Union), and rotigotine (United States and European Union).
b Generic drugs typically are less expensive than brand-name drugs. As of December 2012, generic drugs that also have regulatory approval for
the treatment of RLS/WED include levodopa benserazide, pramipexole, and ropinirole.
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treatments
 At the time of writing these recommendations, there was insuf-
ﬁcient long-term evidence to make a recommendation for any
one opioid. The high-potency opioids (e.g., methadone, oxyco-
done), as a class of medications, however, can be considered
possibly effective (Level C) in the long-term treatment of RLS/
WED refractory to other treatments. Caution should be taken
to exclude sleep-related breathing disorders before treatment
is initiated with opioids, particularly in older patients.
5.5. Recommendation regarding treatment during pregnancy
 In general, pharmacologic treatment should be avoided for RLS/
WED symptoms occurring during pregnancy; both dopamine-
receptor agonists and a2d ligands should be avoided. Consider-
ation should be given to fully replenishing iron stores prior to
pregnancy and maximizing nonpharmacologic treatments. Pub-
lished literature about the practical treatment of RLS during
pregnancy is very limited.
6. Discussion
This thorough review of evidence combined with a clinical con-
sensus process produced signiﬁcant new insights into the state of
RLS/WED treatment. Four are particularly important. First, long-
term treatment considerations changed the recommendations for
initial treatment. Short-term studies of up to 3 months document
safety and efﬁcacy of the current widely approved short-acting
dopamine-receptor agonists, and these drugs are usually consid-
ered to be the ﬁrst choice for the treatment of RLS/WED. However,
the results of long-term studies indicate that the problems of aug-
mentation are serious enough to justify reconsidering whether
short-acting dopamine agonists should always be the initial treat-
ment of choice. Alternative drugs for initial treatment with re-
duced risk for augmentation include the a2d ligands or possiblythe long-acting dopamine-receptor agonists. Thus, this Task Force
recommends that the choice of initial treatment be tailored to
the needs of the patient, largely based on relative signiﬁcance of
the effects and cost of a drug for a particular patient. This choice
is a signiﬁcant advancement and represents a change in the
treatment of RLS/WED.
Second, the process of evaluating long-term RLS/WED treat-
ment studies revealed the inadequacies of typically used evi-
dence-based standards for assessing efﬁcacy in studies of RLS/
WED lasting 6 months or longer. Studies lasting a few months
can and should be placebo controlled, but this is neither practical
nor ethical for long-term studies. Therefore, active-comparator
studies become more important, and the criteria for a positive out-
come need to be adjusted. Ideally, these studies would have an ini-
tial placebo-controlled phase demonstrating short-term efﬁcacy of
the medications. The criterion for long-term efﬁcacy then becomes
maintaining treatment efﬁcacy, as indicated by superiority over
short-term placebo response, and also possibly showing long-term
superiority of one of the active drugs being compared. Thus main-
tained efﬁcacy, rather than superiority over continued long-term
placebo treatment, becomes the critical criterion for evidence-
based long-term treatment of RLS/WED and could be used to de-
ﬁne such studies as Class I studies. We recommend consideration
of this change for deﬁning Class I studies in the future, but, because
implementing this change in deﬁning Class I would have applied to
only one study in our review, we chose to be conservative and did
not apply this change; however, we did adjust the evidence-based
criteria to better handle the wealth of data in our review from care-
fully conducted retrospective studies that inform about long-term
treatments of RLS/WED. The results of these studies need to be in-
cluded in evidenced-based evaluations of long-term treatment as
potentially more than Class IV. In particular, we added a IIIbIRLSSG
category to the typically used Class III criteria for prospective and
a IIIcIRLSSG category for retrospective studies. Tables 2 and 3 present
the criteria we developed for evidence-based long-term treatment
guidelines. We recommend these categories for consideration in
other long-term treatment guideline reviews.
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ment options and outcomes requires attention to expanding the
types of clinical trials being conducted and focusing attention on
the problems associated with long-term treatment, including aug-
mentation. The available studies tend to be relatively short, and in
fact there is only one published prospective study lasting more
than 1 year. More longer-term studies are needed, and a structure
is needed to enable such studies. Other areas identiﬁed by the re-
view process as needing further attention include drug-combina-
tion studies, evaluation of opioids and new treatments, and
development of animal and biologic models of RLS/WED and
augmentation.
Finally, these treatment guidelines were based on available
data, and speciﬁc recommendations were made only when experts
reached consensus. The result is a report that only begins the pro-
cess for producing treatment guidelines for RLS/WED as a chronic
condition. Much more study is needed to meet the long-term treat-
ment needs of patients with RLS/WED.Conﬂict of Interest
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